Axsome Q4 2022 Earnings Report
Key Takeaways
Axsome Therapeutics reported Q4 2022 financial results, with total net sales of $24.4 million, including $5.2 million from Auvelity and $19.2 million from Sunosi. The company's net loss for the quarter was $61.2 million, or $(1.41) per share. The company had cash and cash equivalents of $200.8 million at the end of the year, and a pro forma cash balance in excess of $300 million after considering the Sunosi licensing agreement.
Total net sales for the fourth quarter were $24.4 million.
Auvelity net sales were $5.2 million for the fourth quarter.
Sunosi net sales were $19.2 million for the fourth quarter.
Net loss was $61.2 million, or $(1.41) per share, for the fourth quarter.
Axsome
Axsome
Forward Guidance
Axsome expects that its operating expenses will increase year over year as the Company commercializes Sunosi and Auvelity and continues to advance its pipeline.